Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Fate Therapeutics, Inc. (FATE) had Income from Continuous Operations of $-34.07M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$1.91M |
|
$-34.07M |
|
-- |
|
$1.91M |
|
$38.88M |
|
$-36.97M |
|
$2.90M |
|
$-34.07M |
|
$-34.07M |
|
$-34.07M |
|
|
Income from Continuous Operations |
$-34.07M |
$-34.07M |
|
$-34.07M |
|
$-36.97M |
|
$-34.54M |
|
118.53M |
|
118.53M |
|
$-0.29 |
|
$-0.29 |
|
| Balance Sheet Financials | |
$230.40M |
|
$61.10M |
|
$141.24M |
|
$371.63M |
|
$28.67M |
|
-- |
|
$81.59M |
|
$110.27M |
|
$261.36M |
|
$261.36M |
|
$261.36M |
|
114.66M |
|
| Cash Flow Statement Financials | |
$-58.40M |
|
$62.26M |
|
$1.32M |
|
$46.28M |
|
$51.48M |
|
$5.19M |
|
$14.54M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.04 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1938.54% |
|
-1938.54% |
|
-- |
|
-1786.58% |
|
-1786.58% |
|
$-60.83M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
1.37 |
|
65.84 |
|
-13.04% |
|
-13.04% |
|
-9.17% |
|
-13.04% |
|
$2.28 |
|
$-0.51 |
|
$-0.49 |
|